Targets › MAGE2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.
Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. (UniProt, P43356)
Open in Phaseline: the race on MAGE2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fondazione Ricerca Traslazionale | Tedopi Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5 | CEA, TP53, ERBB2, MAGE2, MAGE3 | Phase 2 | Metastatic Non Small Cell Lung Cancer | Sep 2027 |
Metastatic Non Small Cell Lung Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.